Conditions: Non-Small Cell Lung Cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 122
Healthy volunteers: no

Brief summary:
This study is a multicenter, open-label, two-arm, randomized, parallel Phase 2 feasibility study of pemetrexed in combination with either cisplatin (Arm A) or carboplatin (Arm B) as adjuvant combination-chemotherapy in participants with completely resected, stage Ib or IIa/IIb non-small cell lung cancer (NSCLC).

A two-stage design will be employed independently for both treatment arms, with the possibility of stopping each treatment early for lack of feasibility.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: pemetrexed intervention 2: cisplatin intervention 3: carboplatin
Intervention descriptions: intervention 1: 500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 4 cycles intervention 2: 75 mg/m\^2, intravenous (IV), every 21 days x 4 cycles intervention 3: area under the curve (AUC) 5 milligrams per milliliter\*minute (mg/ml\*min), intravenous (IV), every 21 days x 4 cycles

Protocol document: